

[PA1-14] [04/17/2003 (Thr) 14:00 – 17:00 / Hall P]

Antitumor activity and 3D-Histoculture drug response assay of Novel trans-ditrifluoroacetato,malonato-1,4-butanediamine Pt(IV) complex, K104

Kwon YoungEe^o, Kim KukHwan, Oh BongUn, Kim KapJoon

Drug Discovery Institute, STC Life Science Center, College of Pharmacy Dongduk Women's University

Novel trans-ditrifluoroacetato,malonato-1,4-butanediamine Pt(IV) complex, K104 was synthesized as a chemotherapeutic. The cytotoxicity of K104 against various human cancer cell lines were evaluated by MTS assay in vitro. The IC50 values of K104 ranged 15.83–25.83 μ M, compared to CBCDA ranged 23.24–69.6 μ M. Among several cancer cell lines, K104 showed more potent than CBCDA in colon cancer cell lines. In vivo studies, K104 (30, 50, 100 and 150 mg/kg) was administered by i.p. at day 1, 5, 9 to three animal tumor models compared with CDDP (4 mg/kg) and CBCDA (30 and 60 mg/kg). Antitumor activity (T/C %) of K104 is more potent than CBCDA or CDDP. Especially, K104 showed excellent antitumor activity against BDF1 mice bearing CDDP-resistant cells, L1210/cis-DDP. To evaluate efficacy of K104 against human cancer, the 3D-histoculture drug response assay (HDRA) was performed in 35 cases of colorectal cancer patients. In HDRA, K104 showed 54.3 % efficacy rate compared with 48.6 % of CDDP and 51.4 % of CBCDA against colorectal cancer patient tissues. This study suggests that newly synthesized Pt(IV) complex, K104 appeared to be more effective than CDDP against various antitumor tests.

[PA1-15] [04/17/2003 (Thr) 14:00 – 17:00 / Hall P]

The effects of the novel IDPc inhibitor, DA-11004, on NADPH generation, insulin secretion, and glucose level in obese diabetic (ob/ ob) mice

Lee InKi^o, Shin ChangYell, Sohn JinBup, Jeong MiYoung, Son Miwon, Bae CheolJun, Byun JongSoo, Kim DongSung, Kim SoonHae, Yoo Moohi, Huh TaeLin*, , Kim WonBae

Research Laboratories, Dong-A Pharm. Co. Ltd., 47-5, Sanggal, Kiheung, Yongin, Kyunggi 449-900, Korea. *Department of Genetic Engineering, College of Natural Sciences, Kyung Pook National University

The biological effects of NADPH-dependent isocitrate dehydrogenase (IDPc) inhibitor, DA-11004, was investigated in obese diabetic (ob/ ob) mice. DA-11004, metformin, and oxalomalate were daily injected (ip) for 8 weeks and after completing an 8-week period of experiment, mice were sacrificed at 1hr after the last drugs treatment to collect their blood, liver, and adipose tissues (epididymal and retroperitoneal fat). In the DA-11004 (30mg/kg, ip) treated groups, the increases of body weight and diet consumption were significantly declined when compared to the control groups, but metformin (200mg/kg, ip) or oxalomalate (30mg/kg, ip) had no effects. DA-11004 significantly inhibited the NADPH generation in plasma and synthesis of epididymal and retroperitoneal fat when compared to the control groups ($P < 0.01$). Administration of DA-11004 into ob/ob mice decreased the glucose levels or triglycerides levels in both plasma and liver and the GOT, GPT and LDH levels were also significantly decreased in plasma. However, metformin and oxalomalate had no effects on the GOT, GPT, and LDH levels. Metformin decreased the glucose levels, but oxalomalate had no effects in liver. DA-11004 decreased the plasma insulin responses by 50% when compared to control. In summary, DA-11004 is a synthetic novel IDPc inhibitor, reducing the body weight via inhibition